Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BPR277 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Cohort A and B, BPR277 and Placebo (vehicle) | EXPERIMENTAL | - |
| Part 2 BPR277 | EXPERIMENTAL | - |
| Part 2 Placebo (vehicle) | PLACEBO_COMPARATOR | - |
| Part 3 BPR277 and Placebo (vehicle) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BPR277 ointment (controlled application) | DRUG | - |
| Placebo (Vehicle) | DRUG | - |
| BPR277 ointment | DRUG | - |
| BPR277 | DRUG | - |
Inclusion Criteria: Part 1 Healthy volunteers * Healthy male and female subjects of non childbearing potential, 18 to 65 years of age inclusive and in good health Part 2 Patients with atopic dermatitis: * Male and female subjects, 18 to 65 years of age inclusive and having passed screening exami...
BPR277 is an investigational small molecule being developed by Novartis AG (NVS) for the treatment of atopic dermatitis and Netherton syndrome. It is currently in Phase 1 clinical development and has been studied in healthy volunteers. BPR277 is being evaluated as a topical treatment for these skin conditions.
BPR277 is being studied for the treatment of atopic dermatitis and Netherton syndrome. It is administered topically and has been evaluated in a Phase 1 clinical trial involving healthy volunteers, as well as patients with these conditions. The drug is still in early-stage clinical development and is not yet approved.
BPR277 is being developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol NVS. Novartis is conducting clinical trials to evaluate the safety and efficacy of BPR277 for the treatment of atopic dermatitis and Netherton syndrome.
BPR277 is in Phase 1 clinical development. A Phase 1 trial has been completed, which evaluated the safety and efficacy of topical BPR277 in healthy volunteers and patients with atopic dermatitis and Netherton syndrome. The drug is investigational and has not yet received regulatory approval.
BPR277 has been studied in one completed Phase 1 clinical trial with the identifier NCT01428297. This trial evaluated the safety and efficacy of topical BPR277 for the treatment of atopic dermatitis and Netherton syndrome. The study enrolled 12 participants and was conducted in the United States and the Netherlands.
No alternative names for BPR277 have been reported. The drug is identified solely by its code name BPR277 in clinical trials and development records. It is being developed by Novartis AG for the treatment of atopic dermatitis and Netherton syndrome.